IN2014MN01819A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01819A
IN2014MN01819A IN1819MUN2014A IN2014MN01819A IN 2014MN01819 A IN2014MN01819 A IN 2014MN01819A IN 1819MUN2014 A IN1819MUN2014 A IN 1819MUN2014A IN 2014MN01819 A IN2014MN01819 A IN 2014MN01819A
Authority
IN
India
Prior art keywords
polymeric
disclosed
active agents
therapeutically active
backbone
Prior art date
Application number
Other languages
English (en)
Inventor
Fainaro Ronit Satchi
Ela Markovsky
COHEN Hemda BAABUR
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of IN2014MN01819A publication Critical patent/IN2014MN01819A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1819MUN2014 2012-03-05 2013-03-05 IN2014MN01819A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606557P 2012-03-05 2012-03-05
PCT/IL2013/050195 WO2013132485A1 (fr) 2012-03-05 2013-03-05 Polymères ayant des agents actifs au niveau thérapeutique conjugués à ceux-ci, procédés de préparation desdits polymères et leurs utilisations

Publications (1)

Publication Number Publication Date
IN2014MN01819A true IN2014MN01819A (fr) 2015-07-03

Family

ID=49116032

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1819MUN2014 IN2014MN01819A (fr) 2012-03-05 2013-03-05

Country Status (5)

Country Link
US (2) US9687562B2 (fr)
EP (1) EP2822598A4 (fr)
CN (1) CN104244988A (fr)
IN (1) IN2014MN01819A (fr)
WO (1) WO2013132485A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303288A4 (fr) 2008-05-22 2015-04-22 Univ Ramot Conjugués d'un polymère, d'un bisphosphonate et d'un agent anti-angiogenèse et leurs utilisations dans le traitement et la surveillance de maladies concernant les os
WO2009141826A2 (fr) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Nouveaux conjugués de polymères sur lesquels sont fixés un agent thérapeutiquement actif et une fraction ciblant l'angiogenèse et utilisations de ces conjugués pour traiter des maladies liées à l'angiogenèse
WO2009141827A2 (fr) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugué d'un polymère, d'un agent anti-angiogenèse et d'une fraction de ciblage et utilisations de ce conjugué pour traiter des maladies angiogéniques osseuses
EP2822598A4 (fr) 2012-03-05 2016-04-13 Univ Ramot Polymères ayant des agents actifs au niveau thérapeutique conjugués à ceux-ci, procédés de préparation desdits polymères et leurs utilisations
KR102135679B1 (ko) * 2013-11-19 2020-07-20 삼성전자주식회사 생분해성 폴리머를 포함하는 표적 친화성 물질 및 이의 용도
CN107614019A (zh) * 2015-03-09 2018-01-19 加利福尼亚大学董事会 用于组合抗癌疗法的聚合物‑药物结合物
CN105097941B (zh) * 2015-05-28 2019-02-26 京东方科技集团股份有限公司 一种薄膜晶体管及其制造方法、阵列基板、显示装置
US10478507B2 (en) 2015-10-18 2019-11-19 Ariel-University Research And Development Company Ltd. Peptide-based multiple-drug delivery vehicle
EP3419668A4 (fr) * 2016-02-24 2019-10-09 Ramot at Tel-Aviv University Ltd. Conjugués polymères et leurs utilisations
US11559585B2 (en) 2017-06-16 2023-01-24 The Regents Of The University Of California Conjugates of active pharmaceutical ingredients
WO2019060298A1 (fr) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC Procédé et appareil de neuro-activation
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
EP3731749A4 (fr) 2017-12-31 2022-07-27 Neuroenhancement Lab, LLC Système et procédé de neuro-activation pour améliorer la réponse émotionnelle
EP3737383A4 (fr) 2018-01-12 2021-12-15 Prolynx LLC Traitement synergique du cancer
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020056418A1 (fr) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC Système et procédé d'amélioration du sommeil
EP3891207B1 (fr) 2018-12-04 2022-11-02 TIEN, Der-Yang Stéréocomplexe pour l'administration d'agents anticancéreux
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
EP4045087A4 (fr) * 2019-10-18 2024-03-27 University of Utah Research Foundation Conjugués d'administration de médicaments polymères et leurs procédés de fabrication et d'utilisation
CN111333835B (zh) * 2020-03-06 2021-11-05 同济大学 一种骨靶向聚合物、骨靶向聚合物囊泡及其制备方法与应用
KR20240134314A (ko) * 2021-12-16 2024-09-09 알베올러스 바이오, 인코포레이티드 만성 폐 질환의 치료를 위한 흡입가능한 또는 섭취가능한 락트산 조성물
WO2024054372A1 (fr) * 2022-09-09 2024-03-14 Indiana University Research And Technology Corporation Multivalence pour l'inhibition d'enzymes

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
HUP9802675A3 (en) 1995-08-14 2000-09-28 Scripps Research Inst Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
AU7025600A (en) * 1999-09-08 2001-04-10 School Of Pharmacy, University Of London, The Uniform molecular weight polymers
NZ520458A (en) 2000-02-24 2005-02-25 Genentech Inc Caspase activated prodrugs therapy
CA2444483A1 (fr) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Compositions d'imagerie diagnostique, leurs methodes de synthese et utilisation
AU2003230852B2 (en) 2002-04-11 2008-07-10 Children's Medical Center Corporation TNP-470 polymer conjugates and use thereof
EP1494699A4 (fr) 2002-04-11 2009-07-22 Childrens Medical Center Methodes permettant d'inhiber l'hyperpermeabilite vasculaire
US20030217320A1 (en) 2002-05-20 2003-11-20 Gorshe Steven Scott Cyclic redundancy check circuit for use with self-synchronous scramblers
WO2004062588A2 (fr) 2003-01-06 2004-07-29 University Of Utah Systeme de liberation de medicament polymerique soluble dans l'eau ciblant les os
DE10310082A1 (de) 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
SG160211A1 (en) 2003-04-03 2010-04-29 Semafore Pharmaceuticals Inc Pi-3 kinase inhibitor prodrugs
US20080193377A1 (en) 2004-06-28 2008-08-14 University Of Maryland, Baltimore Radiolabeled Nanohybrids Targeting Solid Tumor Neovasculature and Method of Using Same
WO2006056889A2 (fr) 2004-10-06 2006-06-01 Tiltan Pharma Ltd Procede et composition pour renforcer une therapie anti-angiogenique
US20080248030A1 (en) 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
US8404650B2 (en) 2005-10-28 2013-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating cancer with doxazolidine and prodrugs thereof
US8252740B2 (en) 2006-01-27 2012-08-28 The University Of Mississippi Medical Center Thermally-targeted delivery of medicaments including doxorubicin
WO2008033475A2 (fr) 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Composés cytotoxiques activés destinés à se fixer à des molécules de ciblage dans le traitement de maladies touchant des mammifères
RU2009114154A (ru) 2006-09-15 2010-10-20 Энзон Фармасьютикалз, Инк. (Us) Полимерные пролекарства с направленной доставкой, содержащие полифункциональные линкеры
US20080181852A1 (en) 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101674852A (zh) 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
WO2008141110A2 (fr) 2007-05-09 2008-11-20 Nitto Denko Corporation Conjugués de polyglutamate et conjugués de polyglutamate-amino acide contenant une pluralité de médicaments
CA2723315A1 (fr) * 2008-04-30 2009-11-05 Ben-Gurion University Of The Negev Research And Development Authority Systemes d'administration vasculaire
WO2009141827A2 (fr) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugué d'un polymère, d'un agent anti-angiogenèse et d'une fraction de ciblage et utilisations de ce conjugué pour traiter des maladies angiogéniques osseuses
WO2009141826A2 (fr) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Nouveaux conjugués de polymères sur lesquels sont fixés un agent thérapeutiquement actif et une fraction ciblant l'angiogenèse et utilisations de ces conjugués pour traiter des maladies liées à l'angiogenèse
EP2303288A4 (fr) 2008-05-22 2015-04-22 Univ Ramot Conjugués d'un polymère, d'un bisphosphonate et d'un agent anti-angiogenèse et leurs utilisations dans le traitement et la surveillance de maladies concernant les os
EP2822598A4 (fr) 2012-03-05 2016-04-13 Univ Ramot Polymères ayant des agents actifs au niveau thérapeutique conjugués à ceux-ci, procédés de préparation desdits polymères et leurs utilisations

Also Published As

Publication number Publication date
US20150017115A1 (en) 2015-01-15
WO2013132485A1 (fr) 2013-09-12
EP2822598A4 (fr) 2016-04-13
US20170182176A1 (en) 2017-06-29
CN104244988A (zh) 2014-12-24
US9687562B2 (en) 2017-06-27
WO2013132485A9 (fr) 2014-04-10
US10155047B2 (en) 2018-12-18
EP2822598A1 (fr) 2015-01-14

Similar Documents

Publication Publication Date Title
IN2014MN01819A (fr)
HK1212890A1 (zh) 生物活性分子、其偶聯物及治療用途
EP2563366A4 (fr) Utilisations de conjugués phospholipidiques d'agonistes synthétiques de tlr7
ZA201507218B (en) Compositins and methods for modulating apolipoprotein c-iii expression
NZ708171A (en) Oligonucleotide conjugates
NZ710729A (en) Amatoxin derivatives
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
CR20120202A (es) Métodos y composiciones para tratar cáncer
IN2015DN04147A (fr)
NZ708727A (en) Conjugate compounds
MY177912A (en) Vegf neutralizing prodrugs for the treatment of ocular conditions
MX2015009056A (es) Conjugados de oligonucleotidos de acido nucleico bloqueado y carbohidratos.
EP2307032A4 (fr) Nouveaux conjugués de polymères sur lesquels sont fixés un agent thérapeutiquement actif et une fraction ciblant l'angiogenèse et utilisations de ces conjugués pour traiter des maladies liées à l'angiogenèse
MX2019003249A (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
MX2018013623A (es) Derivados de n-acildipeptido y sus usos.
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
TW201611843A (en) Methods of treatment with arginine deiminase
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
WO2015069697A3 (fr) Polythérapie
EP2925301A4 (fr) Produit thérapeutique et immunomodulateur anticancéreux dhs1p photodynamique
WO2015040243A3 (fr) Procédés et compositions pour cibler un microenvironnement de tumeur et pour prévenir la métastase
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
EP2864345A4 (fr) Conjugués particule-acide nucléique et utilisations thérapeutiques associées
BRPI1009215A2 (pt) "tratamento de câncer com poliptídeos derivados de hiv tat imunoestimulante"